Skip to main content
Top
Published in: Digestive Diseases and Sciences 4/2010

01-04-2010 | Original Article

Preventive Effects of Different Probiotic Formulations on Travelers’ Diarrhea Model in Wistar Rats

Preventive Effects of Probiotics on TD

Authors: Jean-François Bisson, Sophie Hidalgo, Pascale Rozan, Michaël Messaoudi

Published in: Digestive Diseases and Sciences | Issue 4/2010

Login to get access

Abstract

A new animal model of travelers’ diarrhea has been developed by infecting rats orally with a strain of enterotoxigenic Escherichia coli in order to assess the efficacy of three probiotic formulations for the prevention of travelers’ diarrhea. Five groups of six rats were given daily (by oral gavage) either a placebo (negative and positive control groups), the suspension of bacterial probiotics called FF1, the yeast probiotic Saccharomyces boulardii, or a combination of both, called ProtecflorTM. After 14 days of treatment, all groups except the negative control one were infected by oral administration of E. coli. Body temperature, body weight, food and water consumption, stools consistency, behavior, and cytokines secretion were disturbed following E. coli infection. Probiotics-treated groups generally displayed less-pronounced symptoms, the combination of probiotics ProtecflorTM being the most effective.
Literature
1.
go back to reference Yates J. Traveler’s diarrhea. Am Fam Physician. 2005;71:2095–2100.PubMed Yates J. Traveler’s diarrhea. Am Fam Physician. 2005;71:2095–2100.PubMed
7.
go back to reference Billoo AG, Memon MA, Khaskheli SA, et al. Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea. World J Gastroenterol. 2006;12:4557–4560.PubMed Billoo AG, Memon MA, Khaskheli SA, et al. Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea. World J Gastroenterol. 2006;12:4557–4560.PubMed
10.
go back to reference Johnson-Henry KC, Riff JD, Gordanpour M, Sherman PM. Probiotics in models of gastrointestinal infections. Nutrafoods. 2005;4:29–36. Johnson-Henry KC, Riff JD, Gordanpour M, Sherman PM. Probiotics in models of gastrointestinal infections. Nutrafoods. 2005;4:29–36.
11.
12.
go back to reference Martins FS, Nardi RM, Arantes RM, Rosa CA, Neves MJ, Nicoli JR. Screening of yeasts as probiotic based on capacities to colonize the gastrointestinal tract and to protect against enteropathogen challenge in mice. J Gen Appl Microbiol. 2005;51:83–92. doi:10.2323/jgam.51.83.CrossRefPubMed Martins FS, Nardi RM, Arantes RM, Rosa CA, Neves MJ, Nicoli JR. Screening of yeasts as probiotic based on capacities to colonize the gastrointestinal tract and to protect against enteropathogen challenge in mice. J Gen Appl Microbiol. 2005;51:83–92. doi:10.​2323/​jgam.​51.​83.CrossRefPubMed
13.
15.
go back to reference Drisko JA, Giles CK, Bischoff BJ. Probiotics in health maintenance and disease prevention. Altern Med Rev. 2003;8:143–155.PubMed Drisko JA, Giles CK, Bischoff BJ. Probiotics in health maintenance and disease prevention. Altern Med Rev. 2003;8:143–155.PubMed
18.
go back to reference Sazawal S, Hiremath G, Dhingra U, Malik P, Deb S, Black RE. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised placebo-controlled trials. Lancet Infect Dis. 2006;6:374–382.CrossRefPubMed Sazawal S, Hiremath G, Dhingra U, Malik P, Deb S, Black RE. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised placebo-controlled trials. Lancet Infect Dis. 2006;6:374–382.CrossRefPubMed
19.
go back to reference De Simone C, Vesely R, Bianchi BS, Jirillo E. The role of probiotics in modulation of the immune system in man and in animals. Int J Immunother. 1993;9:23–28. De Simone C, Vesely R, Bianchi BS, Jirillo E. The role of probiotics in modulation of the immune system in man and in animals. Int J Immunother. 1993;9:23–28.
20.
22.
go back to reference Marteau PR, De Vrese M, Cellier CJ, Schrezenmeir J. Protection from gastrointestinal diseases with the use of probiotics. Am J Clin Nutr. 2001;73:430–436. Marteau PR, De Vrese M, Cellier CJ, Schrezenmeir J. Protection from gastrointestinal diseases with the use of probiotics. Am J Clin Nutr. 2001;73:430–436.
24.
go back to reference Montalto M, Arancio F, Izzi D, et al. Probiotics: history, definition, requirements and possible therapeutic applications. Ann Ital Med Int. 2002;17:157–165.PubMed Montalto M, Arancio F, Izzi D, et al. Probiotics: history, definition, requirements and possible therapeutic applications. Ann Ital Med Int. 2002;17:157–165.PubMed
27.
go back to reference Lee SK, Kim HJ, Chi SG, et al. Saccharomyces boulardii activates expression of peroxisome proliferator-activated receptor-gamma in HT-29 cells. Korean J Gastroenterol. 2005;45:328–334.PubMed Lee SK, Kim HJ, Chi SG, et al. Saccharomyces boulardii activates expression of peroxisome proliferator-activated receptor-gamma in HT-29 cells. Korean J Gastroenterol. 2005;45:328–334.PubMed
28.
go back to reference Shanahan F. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2005;288:417–421. doi:10.1152/ajpgi.00421.2004.CrossRef Shanahan F. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2005;288:417–421. doi:10.​1152/​ajpgi.​00421.​2004.CrossRef
32.
go back to reference Szajewska H, Skorka A, Dylag M. Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children. Aliment Pharmacol Ther. 2007;25:257–264.PubMedCrossRef Szajewska H, Skorka A, Dylag M. Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children. Aliment Pharmacol Ther. 2007;25:257–264.PubMedCrossRef
33.
go back to reference Can M, Besirbellioglu BA, Avci IY, Beker CM, Pahsa A. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. Med Sci Monit. 2006;12:19–22. Can M, Besirbellioglu BA, Avci IY, Beker CM, Pahsa A. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. Med Sci Monit. 2006;12:19–22.
34.
go back to reference Mc Farland LV, Bernasconi P. Saccharomyces boulardii: a review of an innovative biotherapeutic agent. Microb Ecol Health Dis. 1993;6:157–171.CrossRef Mc Farland LV, Bernasconi P. Saccharomyces boulardii: a review of an innovative biotherapeutic agent. Microb Ecol Health Dis. 1993;6:157–171.CrossRef
39.
go back to reference Sherman PM, Johnson-Henry KC, Yeung HP, Ngo PSC, Goulet J, Tompkins TA. Probiotics reduce enterohemorrhagic Escherichia coli O157:H7- and enteropathogenic E. coli O127:H6-induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements. Infect Immun. 2005;73:5183–5188. doi:10.1128/IAI.73.8.5183-5188.2005.CrossRefPubMed Sherman PM, Johnson-Henry KC, Yeung HP, Ngo PSC, Goulet J, Tompkins TA. Probiotics reduce enterohemorrhagic Escherichia coli O157:H7- and enteropathogenic E. coli O127:H6-induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements. Infect Immun. 2005;73:5183–5188. doi:10.​1128/​IAI.​73.​8.​5183-5188.​2005.CrossRefPubMed
40.
go back to reference Ishida-Fujii K, Sato R, Goto S, et al. Prevention of pathogenic Escherichia coli infection in mice and stimulation of macrophage activation in rats by an oral administration of probiotic Lactobacillus casei I-5. Biosci Biotechnol Biochem. 2007;71:866–873. doi:10.1271/bbb.60464.CrossRefPubMed Ishida-Fujii K, Sato R, Goto S, et al. Prevention of pathogenic Escherichia coli infection in mice and stimulation of macrophage activation in rats by an oral administration of probiotic Lactobacillus casei I-5. Biosci Biotechnol Biochem. 2007;71:866–873. doi:10.​1271/​bbb.​60464.CrossRefPubMed
41.
go back to reference Johnson-Henry KC, Nadjafi M, Avitzur Y, et al. Amelioration of the effects of Citrobacter rodentium infection in mice by pretreatment with probiotics. J Infect Dis. 2005;191:2106–2117. doi:10.1086/430318.CrossRefPubMed Johnson-Henry KC, Nadjafi M, Avitzur Y, et al. Amelioration of the effects of Citrobacter rodentium infection in mice by pretreatment with probiotics. J Infect Dis. 2005;191:2106–2117. doi:10.​1086/​430318.CrossRefPubMed
42.
go back to reference Venkatesan N, Thiyagarajan V, Narayanan S, et al. Anti-diarrhoeal potential of Asparagus racemosus wild root extracts in laboratory animals. J Pharm Pharm Sci.. 2005;8:39–45.PubMed Venkatesan N, Thiyagarajan V, Narayanan S, et al. Anti-diarrhoeal potential of Asparagus racemosus wild root extracts in laboratory animals. J Pharm Pharm Sci.. 2005;8:39–45.PubMed
43.
go back to reference Chitme HR, Chandra R, Kaushik S. Studies on anti-diarrheal activity of Calotropis giganta R.BR. in experimental animals. J Pharm Pharm Sci. 2004;7:70–75.PubMed Chitme HR, Chandra R, Kaushik S. Studies on anti-diarrheal activity of Calotropis giganta R.BR. in experimental animals. J Pharm Pharm Sci. 2004;7:70–75.PubMed
44.
45.
go back to reference Aikawa N, Horikoshi K, Maeda H, Kobayashi H, Ohmori K. Antidiarrheal effects of Zaldaride maleate after oral, intravenous and subcutaneous administration to rats. Jpn J Pharmacol. 1999;81:397–400. doi:10.1254/jjp.81.397.CrossRefPubMed Aikawa N, Horikoshi K, Maeda H, Kobayashi H, Ohmori K. Antidiarrheal effects of Zaldaride maleate after oral, intravenous and subcutaneous administration to rats. Jpn J Pharmacol. 1999;81:397–400. doi:10.​1254/​jjp.​81.​397.CrossRefPubMed
46.
go back to reference Mascolo N, Izzo AA, Barbato F, Capasso F. Inhibition of nitric oxide synthetase prevent castor oil-induced diarrhea in the rat. Br J Pharmacol. 1993;108:861–864.PubMed Mascolo N, Izzo AA, Barbato F, Capasso F. Inhibition of nitric oxide synthetase prevent castor oil-induced diarrhea in the rat. Br J Pharmacol. 1993;108:861–864.PubMed
47.
go back to reference Pinto A, Calignano A, Mascolo N, Autore G, Capasso F. Castor oil increases intestinal formation of platelet-activating factor and acid phosphatase release in the rat. Br J Pharmacol. 1989;96:872–874.PubMed Pinto A, Calignano A, Mascolo N, Autore G, Capasso F. Castor oil increases intestinal formation of platelet-activating factor and acid phosphatase release in the rat. Br J Pharmacol. 1989;96:872–874.PubMed
48.
go back to reference Aikawa N, Karasawa A. Effects of KW-5617 (Zaldaride maleate), a potent and selective calmodulin inhibitor, on secretory diarrhea and on gastrointestinal propulsion in rats. Jpn J Pharmacol. 1998;76:199–206. doi:10.1254/jjp.76.199.CrossRefPubMed Aikawa N, Karasawa A. Effects of KW-5617 (Zaldaride maleate), a potent and selective calmodulin inhibitor, on secretory diarrhea and on gastrointestinal propulsion in rats. Jpn J Pharmacol. 1998;76:199–206. doi:10.​1254/​jjp.​76.​199.CrossRefPubMed
50.
Metadata
Title
Preventive Effects of Different Probiotic Formulations on Travelers’ Diarrhea Model in Wistar Rats
Preventive Effects of Probiotics on TD
Authors
Jean-François Bisson
Sophie Hidalgo
Pascale Rozan
Michaël Messaoudi
Publication date
01-04-2010
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 4/2010
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-009-0822-4

Other articles of this Issue 4/2010

Digestive Diseases and Sciences 4/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine